GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

IMBDX 461030.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

2,325

-2.72%

Close of 5 Nov 2026, in KRW

About IMBDX

Its shares trade on KOSDAQ under the ticker 461030.KQ. It has been listed since 3 April 2024. In the fiscal year to 31 December 2025, it reported revenue of ₩5.33bn and a net loss of ₩7.93bn. At that date it held total assets of ₩27.12bn and shareholders' equity of ₩25.16bn.

IMBDX Inc is a KR-based company operating in industry. The company is headquartered in Seoul, Seoul. The company went IPO on 2024-04-03. IMBDX Inc is a Korea-based company principally engaged in the provision of laboratory analysis services. The firm is principally engaged in the provision of laboratory analysis services such as clinical diagnosis services and genetic analysis services based on liquid biopsy technology. In addition, the Company is also engaged in the development, manufacture and sale of diagnostic products.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
3 Apr 2024
Website
imbdx.com ↗

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • IMBDX Inc provides clinical diagnosis services using liquid biopsy technology in Korea.
  • The company develops and manufactures diagnostic products for laboratory analysis.
  • Seoul-based headquarters supports access to Korea's healthcare infrastructure.

Weaknesses

  • Limited international presence beyond Korea's domestic market.
  • Reliance on liquid biopsy technology for genetic analysis services.
  • Dependence on Korea's healthcare regulatory environment for operations.

Opportunities

  • Expansion into Asia-Pacific markets for laboratory analysis services.
  • Growth in demand for genetic analysis services using liquid biopsy technology.
  • Partnerships with healthcare providers in Korea's growing health sector.

Threats

  • Regulatory changes in Korea affecting laboratory analysis services.
  • Competition from established healthcare providers in Korea.
  • Economic downturns impacting healthcare spending in Korea.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.